AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81.

Stock Market Today 23.10.2025

ENDEDLive coverage has endedEnded: October 25, 2025, 6:00 AM EDT West Pharmaceutical Services Q3 Profit Beats Estimates, Raises FY25 Guidance (WST) October 23, 2025, 7:22 AM EDT. West Pharmaceutical Services (WST) reported a Q3 profit of $140.0 million, or $1.92 per share (GAAP), up from $136.0 million, $1.85 a year earlier. Excluding items, adjusted earnings rose to $142.4 million, or $1.96 per share, versus consensus of about $1.69. Revenue climbed 7.7% to $804.6 million from $746.9 million. Looking ahead, the company issued next-quarter guidance of $1.81-$1.86 for EPS and $790-$800 million for revenue. For FY25, West raised its adjusted-diluted EPS

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

80/100
View full portfolio
Editorial model selection. Not personalised advice.
MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.